trending Market Intelligence /marketintelligence/en/news-insights/trending/zw40fiwljf0ar5qrtjclcq2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Japan approves Gilead's hepatitis B treatment

L.K. Bennett: Bankruptcy Case Study

State Of Singapore Online Video Subscription

Power Forecast Briefing: Capacity Shortfalls to Test the Renewable Energy Transition

Episode 43 - More Change, M&A On Horizon For Equity Research Industry


Japan approves Gilead's hepatitis B treatment

Japan's Ministry of Health, Labour and Welfare approved Gilead Sciences Inc.'s Vemlidy 25 mg for patients with chronic hepatitis B.

"There are currently more than one million people in Japan chronically infected with hepatitis B, and we believe Vemlidy is an important option for patients living with this disease," Gilead Chief Scientific Officer and Executive Vice President of Research and Development, Norbert Bischofberger, said in a statement.

The Gilead drug will compete with GlaxoSmithkline Pharmaceuticals Ltd.'s tenofovir disoproxil fumarate in Japan.